TY - JOUR
T1 - Cooperative group research efforts in lung cancer 2008
T2 - Focus on advanced-stage non-small-cell lung cancer
AU - Wakelee, Heather
AU - Kernstine, Kemp
AU - Vokes, Everett
AU - Schiller, Joan
AU - Baas, Paul
AU - Saijo, Nagahiro
AU - Adjei, Alex
AU - Goss, Glenwood
AU - Gaspar, Laurie
AU - Gandara, David R.
AU - Choy, Hak
AU - Putnam, Joe Bill
N1 - Funding Information:
There are multiple cooperative groups in Japan, including the JCOG, based in Tokyo, which is fully sponsored by the Ministry of Health. The JCOG has an ongoing phase III trial (PC704) for elderly patients with advanced-stage NSCLC who are randomized to receive single-agent docetaxel versus docetaxel and cisplatin. The study aims to enroll 385 patients, with a primary endpoint of OS.
PY - 2008/11
Y1 - 2008/11
N2 - Clinical trials performed within the cooperative group system play a substantial role in the advancing of lung cancer therapy. Interactions between the leaders of the cooperative groups are critical and occur regularly throughout the year, but the annual Lung Cancer Congress provides a unique forum for representatives from each group to present ongoing and planned studies in an interactive forum. Herein, we highlight discussion from the 9th annual Lung Cancer Congress in June 2008, focused on advanced-stage non-small-cell lung cancer (NSCLC). Many studies are looking at the addition of targeted agents such as bevacizumab, cetuximab, vascular endothelial growth factor receptor inhibitors, and apoptosis-inducing agents to chemotherapy. Personalizing therapy by better selection of patients for particular drugs is also being emphasized, most notably epidermal growth factor receptor fluorescence in situ hybridization overexpression and other predictions of response with cetuximab. Future articles in this series will address early and locally advanced NSCLC as well as other thoracic malignancies such as small-cell lung cancer and mesothelioma. Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer.
AB - Clinical trials performed within the cooperative group system play a substantial role in the advancing of lung cancer therapy. Interactions between the leaders of the cooperative groups are critical and occur regularly throughout the year, but the annual Lung Cancer Congress provides a unique forum for representatives from each group to present ongoing and planned studies in an interactive forum. Herein, we highlight discussion from the 9th annual Lung Cancer Congress in June 2008, focused on advanced-stage non-small-cell lung cancer (NSCLC). Many studies are looking at the addition of targeted agents such as bevacizumab, cetuximab, vascular endothelial growth factor receptor inhibitors, and apoptosis-inducing agents to chemotherapy. Personalizing therapy by better selection of patients for particular drugs is also being emphasized, most notably epidermal growth factor receptor fluorescence in situ hybridization overexpression and other predictions of response with cetuximab. Future articles in this series will address early and locally advanced NSCLC as well as other thoracic malignancies such as small-cell lung cancer and mesothelioma. Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer.
KW - Chemotherapy
KW - Clinical trials
KW - Epidermal growth factor receptor
KW - Fluorescence in situ hybridization
UR - http://www.scopus.com/inward/record.url?scp=59449106057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59449106057&partnerID=8YFLogxK
U2 - 10.3816/CLC.2008.n.050
DO - 10.3816/CLC.2008.n.050
M3 - Article
C2 - 19073517
AN - SCOPUS:59449106057
SN - 1525-7304
VL - 9
SP - 346
EP - 351
JO - Clinical lung cancer
JF - Clinical lung cancer
IS - 6
ER -